During the annual meeting of the Radiological Society of North America, GE Healthcare presented a new standard in breast cancer management designed to assist physicians in administering tailored screening and diagnostic procedures in an all-inclusive environment, complete with 3D breast tomosynthesis, automated breast ultrasound (ABUS), contrast-enhanced spectral mammography (CESM), molecular breast imaging (MBI), breast magnetic resonance imaging (MRI), and healthcare IT workflows connecting them together.
The new Boca Raton Regional Hospital in Florida is the first medical institution in the country to adopt GE Healthcare’s extensive lineup of breast care solutions to offer women a “one-stop-shop” for all their concerns on breast health, with the added security of knowing the procedures they elect are entirely individualized.
Dr. Kathy Schilling, the medical director of Christine E. Lynn Women’s and Wellness Institute of Boca Raton Regional Hospital, expressed the institution’s commitment in making breast cancer screening and treatment less of an ordeal for women, without compromising quality, precision and thoroughness. “Based on individualized needs, our patients now have access to GE Healthcare’s 3D tomosynthesis, advanced mammography, SensorySuite, CESM, ABUS, breast MRI, and MBI – all tied together by GE’s Centricity Solutions for Enterprise Imaging software. By offering one comprehensive solution in one place, we want to provide one day diagnoses for more patient-centered care”, Dr.Schilling said in a press release.
Jessie Jacob, MD, MMM, the chief medical officer of Breast Health at GE Healthcare, believes it is high time for oncologists to employ one interconnected solution that makes breast cancer screening and management less intimidating, stressful, and costly for each unique woman. “This future starts today”, said Dr. Jacob.
[adrotate group=”3″]
Included in GE Healthcare’s comprehensive breast care solutions are two unparalleled technologies that were revealed earlier in the year: the SenoClaire and Invenia ABUS. The SenoClaire is a first class 3D breast tomosynthesis tool designed to detect breast cancer within all types of breast tissue, without the worry of being exposed to more radiation than that expected from a traditional 2D mammogram. It utilizes a “step-and-shoot” method that eliminates blurring and enhances image sharpness. Invenia ABUS is the first of its kind to be approved by the US Food and Drug Administration for the accurate screening of the 40% of women with dense breast tissue. GE Healthcare is the only company to offer these two world-class breast cancer technologies that combine precision medicine with patient-centered cancer care.